Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

319 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response.
Kaufman DS, Winter KA, Shipley WU, Heney NM, Chetner MP, Souhami L, Zlotecki RA, Sause WT, True LD. Kaufman DS, et al. Among authors: true ld. Oncologist. 2000;5(6):471-6. doi: 10.1634/theoncologist.5-6-471. Oncologist. 2000. PMID: 11110598 Free article. Clinical Trial.
Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03.
Shipley WU, Winter KA, Kaufman DS, Lee WR, Heney NM, Tester WR, Donnelly BJ, Venner PM, Perez CA, Murray KJ, Doggett RS, True LD. Shipley WU, et al. Among authors: true ld. J Clin Oncol. 1998 Nov;16(11):3576-83. doi: 10.1200/JCO.1998.16.11.3576. J Clin Oncol. 1998. PMID: 9817278 Clinical Trial.
Novel neoadjuvant therapy paradigms for bladder cancer: results from the National Cancer Center Institute Forum.
Dinney CP, Hansel D, McConkey D, Shipley W, Hagan M, Dreicer R, Lerner S, Czerniak B, Waldman F, Groshen S, True LD, Petricoin E, Theodorescu D, Hruszkewycz A, Bajorin D. Dinney CP, et al. Among authors: true ld. Urol Oncol. 2014 Nov;32(8):1108-15. doi: 10.1016/j.urolonc.2013.10.021. Epub 2014 Oct 24. Urol Oncol. 2014. PMID: 25443274 Free PMC article. Review.
Radiation Therapy Oncology Group. Research Plan 2002-2006. Genitourinary Cancer Committee.
Sandler H, Shipley WU, Gomella L, Pienta K, Bard RH, Bruner D, Clark R, DeSilvio M, Gaspar L, Gillin M, Grignon D, Hammond E, Hanks G, Heydon KH, Kaufman DS, Lee WR, Michalski J, Mydlo J, Pisansky T, Pollack A, Porterfield H, Rifkin M, Roach M 3rd, Sanda M, True L, Vijayakumar S, Winter KA, Zeitman A; Radiation Therapy Oncology Group. Sandler H, et al. Int J Radiat Oncol Biol Phys. 2001;51(3 Suppl 2):28-38. Int J Radiat Oncol Biol Phys. 2001. PMID: 11641012 No abstract available.
Association of Tissue Abiraterone Levels and SLCO Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate Cancer.
Mostaghel EA, Cho E, Zhang A, Alyamani M, Kaipainen A, Green S, Marck BT, Sharifi N, Wright JL, Gulati R, True LD, Loda M, Matsumoto AM, Tamae D, Penning TN, Balk SP, Kantoff PW, Nelson PS, Taplin ME, Montgomery RB. Mostaghel EA, et al. Among authors: true ld. Clin Cancer Res. 2017 Aug 15;23(16):4592-4601. doi: 10.1158/1078-0432.CCR-16-2245. Epub 2017 Apr 7. Clin Cancer Res. 2017. PMID: 28389510 Free PMC article. Clinical Trial.
Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors.
Chen EJ, Sowalsky AG, Gao S, Cai C, Voznesensky O, Schaefer R, Loda M, True LD, Ye H, Troncoso P, Lis RL, Kantoff PW, Montgomery RB, Nelson PS, Bubley GJ, Balk SP, Taplin ME. Chen EJ, et al. Among authors: true ld. Clin Cancer Res. 2015 Mar 15;21(6):1273-80. doi: 10.1158/1078-0432.CCR-14-1220. Epub 2014 Oct 15. Clin Cancer Res. 2015. PMID: 25320358 Free PMC article.
Radiation Therapy Oncology Group. Research Plan 2002-2006. Pathology Committee.
Grignon D, Amin M, Brat D, El-Nagaar A, Hammond E, Lucas D, Nelson J, Petito C, Scott C, Sheahan DG, Sneige N, True L, Yesner R; Radiation Therapy Oncology Group. Grignon D, et al. Int J Radiat Oncol Biol Phys. 2001;51(3 Suppl 2):110-2. Int J Radiat Oncol Biol Phys. 2001. PMID: 11641025 No abstract available.
Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents.
Dancey JE, Dobbin KK, Groshen S, Jessup JM, Hruszkewycz AH, Koehler M, Parchment R, Ratain MJ, Shankar LK, Stadler WM, True LD, Gravell A, Grever MR; Biomarkers Task Force of the NCI Investigational Drug Steering Committee. Dancey JE, et al. Among authors: true ld. Clin Cancer Res. 2010 Mar 15;16(6):1745-55. doi: 10.1158/1078-0432.CCR-09-2167. Epub 2010 Mar 9. Clin Cancer Res. 2010. PMID: 20215558
Practice patterns related to prostate cancer grading: results of a 2019 Genitourinary Pathology Society clinician survey.
Fine SW, Trpkov K, Amin MB, Algaba F, Aron M, Baydar DE, Beltran AL, Brimo F, Cheville JC, Colecchia M, Comperat E, Costello T, da Cunha IW, Delprado W, DeMarzo AM, Giannico GA, Gordetsky JB, Guo CC, Hansel DE, Hirsch MS, Huang J, Humphrey PA, Jimenez RE, Khani F, Kong MX, Kryvenko ON, Kunju LP, Lal P, Latour M, Lotan T, Maclean F, Magi-Galluzzi C, Mehra R, Menon S, Miyamoto H, Montironi R, Netto GJ, Nguyen JK, Osunkoya AO, Parwani A, Pavlovich CP, Robinson BD, Rubin MA, Shah RB, So JS, Takahashi H, Tavora F, Tretiakova MS, True L, Wobker SE, Yang XJ, Zhou M, Zynger DL, Epstein JI. Fine SW, et al. Urol Oncol. 2021 May;39(5):295.e1-295.e8. doi: 10.1016/j.urolonc.2020.08.027. Epub 2020 Sep 15. Urol Oncol. 2021. PMID: 32948433 Free PMC article.
319 results